Japan Pricing Methodology Analogue Assessment von Park, S, Fatoo, A, Yampolsky, D, Martin de Bustamante, M

Volltext

Time to Reimbursement for Oncology Agents from EMA Marketing Authorization to AIFA Approval AS “C(NN)” Class versus. AIFA Approval AS “A” or “H” Class von Monoson, L, Martin de Bustamante, MA, Beckerman, R

Volltext

HPR103 Potential Impacts of the EMA-HMA Join Statement Supporting Biosimilar Interchangeability in Biosimilar Access in the EU von Ribeiro, A., Sazakli, E.A., O'Hara, M., Martin De Bustamante, M.

Volltext

PNS72 From Volume-to-VALUE in Latin America: A 6-STEP Process von Guarin, D., Bustos Márquez, M.C., Izquierdo Albero, R., Boers Trilles, V., Martin De Bustamante, M.

Volltext

PMU9 ESTABLISHING CHILE RICARTE SOTO LAW REIMBURSEMENT CAP IN THE FACE OF GENERIC COMPETITION von Boers Trilles, V., Martin De Bustamante, M.

Volltext

PIN63 Choosing the Right COVID-19 Vaccine: A Multiple Stakeholder Multicriteria Decision Analysis For the Assessment of Available Vaccines in Latin America von Espinoza, M.A., Guzman, J., Soto, J., Hernandez, G., Guarin, D., Boers Trilles, V., Martin De Bustamante, M.

Volltext

PNS101 COLLABORATIVE APPROACHES TO ATTAIN HEALTHCARE SUSTAINABILITY IN LATIN AMERICA von Guarin, D.F., Chavez, R., Trujillo de Hart, J.C., Graham, N., Boers Trilles, V., Martin De Bustamante, M.

Volltext

PHP180 - ACCESS AND VALUE OF HEALTHCARE INNOVATION IN LATIN AMERICA von Martin de Bustamante, M., Alfonso, R., Boers Trilles, V., Guarin, D.F.

Volltext

PNS32 COMPARATIVE ANALYSIS OF TENDER LEGISLATION IN BRAZIL AND MEXICO von Boers Trilles, V., Favetta, B., Martin De Bustamante, M.

Volltext

PDG22 Comparison of Healthcare Systems and Opportunities for Innovative Drugs across India, Vietnam, and Indonesia von Yeow, I., O'Toole, G., Broadhurst, M., Zhang, W., Martin De Bustamante, M.

Volltext

PHP115 - Japan Pricing Methodology Analogue Assessment von Park, S., Fatoo, A., Yampolsky, D., Martin de Bustamante, M.

Volltext

What are the Key Driving Factors Behind RSA Decisions In Australia? von Nash, P, Martin de Bustamante, M.A

Volltext

PNS3 BRAZILIAN PHARMACEUTICAL INDUSTRY: THE IMPACT OF PUBLIC POLICIES AIMED AT FOSTERING LOCAL MANUFACTURING von Boers Trilles, V., Ayoub, R., Favetta, B., Martin De Bustamante, M.

Volltext

PMU11 COMPARATIVE ASSESSMENT OF HTA OUTCOMES IN BRAZIL, CANADA AND THE UNITED KINGDOM von Boers Trilles, V., Ayoub, R., Favetta, B., Graham, N., Martin De Bustamante, M.

Volltext

PNS2 COLOMBIA'S HEALTHCARE REFORM: COST-CONTAINMENT MECHANISMS AND IMPLICATIONS FOR SUSTAINABILITY von Boers Trilles, V., Favetta, B., Du, A., Martin De Bustamante, M.

Volltext

PCN3 BRAND-BRAND ONCOLOGY COMBINATIONS: HURDLES AND IMPLICATIONS von Boers Trilles, V., Favetta, B., Garcia, E., Graham, N., Martin De Bustamante, M.

Volltext

PCN45 COMPARATIVE ANALYSIS OF BRA CMED, GER G-BA AND FRA HAS ASSESSMENT SCORES FOR ONCOLOGY THERAPIES von Boers Trilles, V., Favetta, B., Graham, N., Martin De Bustamante, M.

Volltext

PCN60 - Regulatory Approval for Oncology Products In Brazil: A Comparison Between The Fda And Anvisa Approval Timelines von Martin de Bustamante, M, Martin de Bustamante, M, Duttagupta, S, Beckerman, R, Smith, NJ, Roitberg, F, Lopes, G

Volltext

Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RR... von Meletiche, D.M, Rutkowski, T, Martin de Bustamante, M.A, Chowdhury, C.A, Beckerman, R

Volltext

Regulatory Approval for Oncology Products In Brazil : A Comparison Between The Fda And Anvisa Approval Timelines von Martin de Bustamante, M, Duttagupta, S, Beckerman, R, Smith, NJ, Roitberg, F, Lopes, G

Volltext